Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sample size computation for two-sample noninferiority log-rank test.

Sin-Ho Jung1, Sun J Kang, Linda M McCall

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. jung0005@mc.duke.edu

Journal of Biopharmaceutical Statistics
|November 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Research square·2026
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study.

American journal of veterinary research·2025
Same author

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.

Thorax·2025
Same author

Design and analysis of individually randomized group-treatment trials with time to event outcomes.

Lifetime data analysis·2025
Same author

Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial.

JAMA internal medicine·2025
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study introduces a modified log-rank test and a new sample size formula for noninferiority trials with survival endpoints. These methods help design clinical trials comparing new therapies against standard ones.

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Survival Analysis

Background:

  • Noninferiority trials are crucial when experimental therapies offer advantages like reduced toxicity or cost.
  • Standard statistical methods may require modification for noninferiority designs with survival endpoints.

Purpose of the Study:

  • To present a modified log-rank test suitable for noninferiority trials with survival data.
  • To propose and validate a novel sample size formula for designing such trials.

Main Methods:

  • The study modifies the traditional log-rank test for noninferiority hypothesis testing.
  • A new sample size formula is derived for planning noninferiority trials.
  • Simulations are used to evaluate the performance of the proposed sample size formula.

Related Experiment Videos

Main Results:

  • The modified log-rank test is appropriate for assessing noninferiority in survival trials.
  • The proposed sample size formula provides a reliable basis for trial design.
  • The formula's performance was validated through simulation studies.

Conclusions:

  • The developed statistical methods and sample size formula are valuable tools for designing noninferiority clinical trials.
  • These advancements facilitate the evaluation of potentially advantageous experimental therapies compared to standard treatments.